Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

Authors: Alessandro Broccoli, Laura Nanni, Vittorio Stefoni, Claudio Agostinelli, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytostatic drugs.

Case presentation

We report a case of nodal, HIV-unrelated PBL in a patient who achieved and maintained a very long lasting complete remission after an intensive therapy consisting consisting of thalidomide plus dexamethasone followed by a consolidation with double autologous stem cell transplantation. Our approach was based on the full application of a standard multiple myeloma treatment and, to the best of our knowledge, it represents the only reported experience so far. This treatment was overall well tolerated.

Conclusions

Multiple myeloma-like treatment may represent a possible alternative to intensive lymphoma-directed therapies.
Literature
1.
Campo E, Stein H, Harris NL. Plasmablastic lymphoma In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al, Eds. IARC Press, Lyon, France, Revised 4th edition; 2017. p. 317, 321–322.
2.
Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826–31.PubMed
3.
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–30.CrossRefPubMed
4.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991–9.CrossRefPubMed
5.
Valera A, Balagué O, Colomo L, Martínez A, Delabie J, Taddesse-Heath L, et al. Ig/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686–94.PubMedPubMedCentral
6.
Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15:293–9.CrossRefPubMedPubMedCentral
7.
Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic stem cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877–84.CrossRefPubMed
8.
Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36:287–91.CrossRefPubMed
9.
Yan M, dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77–80.CrossRefPubMed
10.
Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352–5.CrossRefPubMed
11.
Hirosawa M, Morimoto H, Shibuya R, Shimajiri S, Tsukada J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res. 2015;3:28.CrossRefPubMedPubMedCentral
12.
Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, et al. Infusional dose-adjusted EPOCH plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016;95:667–8.CrossRefPubMed
13.
Cencini E, Fabbri A, Guerrini S, Mazzei MA, Rossi V, Bocchia M. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016;96:650–4.CrossRefPubMed
14.
Carras S, Regny C, Peoc’h M, Gervasoni J, Gressin R, Cahn JY, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leuk Lymphoma. 2015;56:2986–8.CrossRefPubMed
15.
Schmit JM, DeLaune J, Norkin M, Grosbach A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol Rest Treat. 2017;40:46–8.CrossRef
Metadata
Title
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report
Authors
Alessandro Broccoli
Laura Nanni
Vittorio Stefoni
Claudio Agostinelli
Lisa Argnani
Michele Cavo
Pier Luigi Zinzani
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4561-9

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Clinicopathological features, surgical strategy and prognosis of duodenal gastrointestinal stromal tumors: a series of 300 patients

Research article

Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma

Research article

Pattern of care of prostate cancer patients across the Martinique: results of a population-based study in the Caribbean

Research article

Gene expression profiles in genome instability-based classes of colorectal cancer

Research article

Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins

Research article

Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits